Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 3/20 | 0.43 |
| ▸ | MGLL | Q99685 | 3/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
| ▸ | CTRC | Q99895 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
| ▸ | RHOA | P61586 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17779977 | 0.87 | KMO (0.55) | KMO | |
| SCHEMBL16108712 | 0.82 | PARP1 (0.52) | MGLL | |
| SCHEMBL16108643 | 0.82 | MAPT (0.47) | RXRARXRBMAP4K4KMO | |
| SCHEMBL17779987 | 0.80 | KMO (0.50) | CNR1MGLLKMO | |
| SCHEMBL16108013 | 0.78 | CES2 (0.60) | MGLL | |
| SCHEMBL16108333 | 0.78 | RXFP1 (0.37) | KAT6ARXRARXRBKMO | |
| SCHEMBL16108140 | 0.77 | PAX8 (0.47) | KAT6A | |
| SCHEMBL16109170 | 0.77 | KMO (0.61) | KMO | |
| SCHEMBL16108159 | 0.77 | CES2 (0.57) | KAT6A | |
| SCHEMBL16108592 | 0.76 | MKNK1 (0.43) | RXRARXRBKMORHOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353089-B2 | Compositions and methods for the treatment of malaria | SAINT LOUIS UNIVERSITY (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140296532-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296532-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | BACE2, DNPEP, ACE | SUCNR1 2994/4885KAT6A 2175/4885RXRA 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.